In a recent interview with The Daily Mail, Andrew Steele, author of "Ageless: The New Science of Getting Older Without Getting Old," shared his insights on the future of aging. Steele states, "I'd be shocked if in five years we don't have some senolytics in the clinic. It probably won't be for aging at first. It'll be for a specific disease - and maybe in 10 years, we'll use it for aging. These things are very, very near term." This market revolves around Steele's vision of senolytics being clinically utilized for anti-aging. Senolytics are drugs that target and eliminate senescent cells. The question at hand: Will we see credible reports describing the successful use of senolytics in a clinical setting specifically for anti-aging by the end of 2033? If prior to the deadline, news articles or medical journals confirm such use of senolytics for anti-aging outside of trial phases, the market resolves to YES. If there's no such confirmation, the market resolves to NO. As the creator, I will abstain from betting in this market.